{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:44:55Z","timestamp":1762508695517,"version":"3.41.2"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Metastatic thymic carcinomas have a poor prognosis. Pembrolizumab, an anti-PD-1 antibody, has recently been evaluated for patients with metastatic thymic carcinomas progressing after at least one line of platinum-based chemotherapy. The antitumor activity of immunotherapy appears to be promising for these patients and pembrolizumab in monotherapy is actually a treatment option in second metastatic line. To the best of our knowledge, we report the first case of a patient treated for metastatic thymic adenocarcinoma with a combination of chemotherapy\u2013immunotherapy. The patient is a 46-year-old man with metastatic thymic adenocarcinoma treated in third metastatic line with a combination of pembrolizumab plus platinum-based chemotherapy with a very good metabolic tumor response. He had a progression-free survival of 7.9 months and did not experience any severe side effects related to pembrolizumab. The association of immunotherapy and chemotherapy, as in non-small cell and small cell lung cancers, could be of interest for future therapeutic trials evaluating the survival of patients with metastatic thymic carcinoma.<\/jats:p>","DOI":"10.3389\/fonc.2021.814544","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T05:14:55Z","timestamp":1642655695000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report"],"prefix":"10.3389","volume":"11","author":[{"given":"Quentin Dominique","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Basse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Luporsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes","volume":"10","author":"Marx","year":"2015","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu541","article-title":"A Multicenter Phase II Study of Carboplatin and Paclitaxel for Advanced Thymic Carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin Plus Doxorubicin Plus Cyclophosphamide in Metastatic or Recurrent Thymoma: Final Results of an Intergroup Trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.005","article-title":"Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights From the RYTHMIC Prospective Cohort","volume":"13","author":"Merveilleux du Vignaux","year":"2018","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in Patients With Thymic Carcinoma: A Single-Arm, Single-Centre, Phase 2 Study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000290","article-title":"The IASLC\/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors","volume":"9","author":"Detterbeck","year":"2014","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab Plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11864-019-0652-3","article-title":"When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer","volume":"20","author":"Mhanna","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune Checkpoint Inhibitors for Patients With Advanced Lung Cancer and Oncogenic Driver Alterations: Results From the IMMUNOTARGET Registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.814544\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T05:14:58Z","timestamp":1642655698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.814544\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":12,"alternative-id":["10.3389\/fonc.2021.814544"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.814544","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"article-number":"814544"}}